Trial Profile
A study assessing long-term clinical outcomes in diabetes mellitus patients following percutaneous coronary intervention with a second-generation drug-eluting stent Xience
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis
- Focus Adverse reactions
- 29 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology